Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).

ABSTRACT: The newly developed concept of oncogene addiction provides a rationale for the use of targeted therapies. In sharp contrast to the field of breast cancer treatment, attempts to target human epidermal growth factor receptor 2 (HER2) among gastric cancer (GC) patients have been unsatisfactory. The ToGA trial reported only a modest prolongation of progression-free survival (PFS) with trastuzumab and the subsequent TYTAN and LOGiC trials failed to demonstrate any survival advantage with lapatinib. These results suggest that a response to the molecular-targeted therapies is achieved in only a fraction of the patients; in addition, even responders may experience secondary resistance, with the efficacy of the treatment being decreased or abrogated over a short period of time. Considering the incr

SUBMITTER: Shimoyama S 

PROVIDER: S-EPMC3917765 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature